- Thromb-X
Thromb-X is a Belgian biotech company. It was founded by Professor
Désiré Collen , an expert incardiovascular disease, of theKatholieke Universiteit Leuven and head of the "VIB Departement of Transgene Technology and Gene Therapy, K.U.Leuven".History
Thromb-X was founded in
1991 , as a spin-off company ofKatholieke Universiteit Leuven . The company was constituted jointly by K.U.Leuven R&D and Prof. Désiré Collen. In1999 ThromboGenics Ltd., (Dublin ,Ireland ), became the majority shareholder of Thromb-X and Thromb-X became the R&D subsidiary of Thrombogenics.Thromb-X was established to develop
tissue plasminogen activator (tPA), a thrombolytic agent, as a treatment of acute myocardial infarction (heart attack) [Collen D, Billiau A, Edy J, De Somer P., Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells, Biochim Biophys Acta. 1977 Sep 29;499(2):194-201] [Collen D, Verstraete M. Systemic thrombolytic therapy of acute myocardial infarction? Circulation. 1983 Aug;68(2):462–465] [Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation. 1985 Jul;72(1):18–20] [Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M., Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction, Circulation. 1986 Mar;73(3):511–517] .References
ource
* [http://www.drugresearcher.com/news/ng.asp?id=74190-thrombogenics-bioinvent-anticoagulant-tb-factor-viii Thrombogenics and Bioinvent trial anticoagulant]
* [http://www.flandersbio.be/organization_detail2.asp?id_org=43 Thromb-X]External links
* [http://www.thrombogenics.com/ ThromboGenics]
Wikimedia Foundation. 2010.